drugset / Trial / NCT02289300
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether an investigational drug DCB-BO1202 is effective and safe in the treatment of liver fibrosis in HBV patients having experienced intermediate stage hepatocellular carcinoma (HCC)
Timeline
- Start
- 2020-01
- Primary completion
- 2021-01
- Completion
- 2021-12
Outcome
Outcome not reported
Stopped: “At sponsor's discretion”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCB-BO1202 | Unknown | 300 mg | Oral |
| Subject | DCB-BO1202 | Unknown | 600 mg | Oral |